Bristol-Myers Squibb Company
BMY · Healthcare · Pharmaceuticals
Updated 26 min ago · data delayed ≥15 min
IconicScore
ProprietaryRanked #105 of 500 by Iconic Score · #14 of 59in its sector. IconicAlpha’s proprietary brand-intelligence metric — a multi-model blend of scale, market attention, category leadership, and AI-analyzed brand visibility.
Get the free morning email
The biggest IconicScore™ gainer and loser, plus the strongest and weakest sectors, in your inbox before the open. See a sample →
Price performance
Export history · AnalystThis insight is part of the Analyst tier — unlock the IconicScore vs. price overlay, side-by-side comparison, and CSV export.
Upgrade to AnalystThis is part of the Enterprise tier — benchmark your IconicScore against sector peers, claim your profile, and manage how your brand appears on the wall.
Upgrade to EnterpriseIconic Profile
Bristol-Myers Squibb Co (BMY) is a leading global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases. With a market capitalization of $117.6 billion, the company has a strong position in the healthcare sector, particularly in oncology, immunology, and cardiovascular disease treatments. Bristol-Myers Squibb's robust pipeline and commitment to research and development enable it to address unmet medical needs and enhance patient outcomes. Its portfolio includes several blockbuster drugs, which contribute significantly to its revenue and market presence. The company's strategic collaborations and acquisitions further strengthen its capabilities and competitive edge, making it a key player in the evolving pharmaceutical landscape.
IconicOracleAI™ Brief
Bristol-Myers Squibb Co (BMY) currently holds an Iconic Score of 58, reflecting moderate brand strength amid competitive pressures from peers like AbbVie and Amgen. The company's ability to navigate challenges related to its key drug portfolio, particularly in light of potential generic competition, has garnered attention, impacting overall sentiment. Despite a recent price decline of 1.13%, BMY maintains strong brand visibility with a score of 85/100, indicating solid recognition in the market.
AI-generated explanation of current score drivers. Not investment advice.
Enterprise tier: claim your logo to manage how your brand is represented.